Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
- Nichi-Iko to Succeed 2 Off-Patent Brands from Astellas
October 30, 2019
- Debiopharm on Hunt for Japanese Ally for 1st-in-Class Cancer Drug, Eyes PIII Launch in 2020
October 29, 2019
- To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
- Desalex Resupply Scheduled from Nov. 18: Kyorin
October 29, 2019
- Astellas’ Kidney Injury Med Gets FDA’s Fast Track Status
October 29, 2019
- AbbVie Embarking on Work Style Reform for Sales Reps, Lets Staffers Pick Locations
October 28, 2019
- With European OK, Astellas’ Xospata Extends Lead over Daiichi Sankyo’s FLT3 Rival
October 28, 2019
- Mitsubishi Tanabe Ups H1 Earnings Forecast
October 28, 2019
- Nichi-Iko to Gradually Resume Cefazolin Supply from Nov. 25
October 28, 2019
- General Phenotypes of Psychiatric Disorders Observed in iPS Cell Research: Sumitomo Dainippon, Keio Univ., Nagoya Univ.
October 25, 2019
- Chugai Notches Up Record Earnings in January-September on Hemlibra, Mainstays
October 25, 2019
- Shionogi to Focus on Safety, Not Sales, in Detailing Xofluza
October 25, 2019
- Ohara Launches Class I Recall for Nizatidine over Carcinogen Risks
October 24, 2019
- Takeda Bags Worldwide Rights for Cour's Celiac Disease Treatment
October 24, 2019
- RWD Suggests Lower Serious Adverse Event Risks for Entyvio vs. Anti-TNFα Antibodies: Takeda
October 24, 2019
- Zolgensma’s Japan Launch Delayed into 2020 as Sakigake Review Drags On, MHLW Still Eager to Make Decision by Year-End
October 23, 2019
- Tecentriq plus Avastin Extend OS, PFS in 1st Line HCC
October 23, 2019
- In Shocking U-Turn, Biogen/Eisai Say to File Aducanumab in Early Next Year
October 23, 2019
- Parexel Looks to Set Itself Apart from Rivals through Consulting Services
October 23, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…